TransMedics Group (TMDX) Set to Announce Quarterly Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) will likely be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.2976 per share and revenue of $178.06 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 earnings per share. On average, analysts expect TransMedics Group to post $1.46 EPS for the current fiscal year and $2.26 EPS for the next fiscal year.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $66.67 on Tuesday. The company has a 50 day moving average of $81.09 and a 200 day moving average of $94.54. The stock has a market cap of $2.30 billion, a P/E ratio of 17.14, a P/E/G ratio of 0.92 and a beta of 1.94. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill purchased 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the purchase, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMDX. UBS Group decreased their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. TD Cowen restated a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Canaccord Genuity Group decreased their target price on TransMedics Group from $95.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a report on Friday, September 11th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and a consensus price target of $115.60.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.